An Activatable Theranostic for Targeted Cancer Therapy and Imaging**
- Authors
- Bhuniya, Sankarprasad; Maiti, Sukhendu; Kim, Eun-Joong; Lee, Hyunseung; Sessler, Jonathan L.; Hong, Kwan Soo; Kim, Jong Seung
- Issue Date
- 22-4월-2014
- Publisher
- WILEY-V C H VERLAG GMBH
- Keywords
- biotin; cellular imaging; glutathione; SN-38; theranostic
- Citation
- ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, v.53, no.17, pp.4469 - 4474
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Volume
- 53
- Number
- 17
- Start Page
- 4469
- End Page
- 4474
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/98743
- DOI
- 10.1002/anie.201311133
- ISSN
- 1433-7851
- Abstract
- A new theranostic strategy is described. It is based on the use of an all in one prodrug, namely the biotinylated piperazine-rhodol conjugate 4a. This conjugate, which incorporates the anticancer drug SN-38, undergoes self-immolative cleavage when exposed to biological thiols. This leads to the tumor-targeted release of the active SN-38 payload along with fluorophore 1a. This release is made selective as the result of the biotin functionality. Fluorophore 1a is 32-fold more fluorescent than prodrug 4a. It permits the delivery and release of the SN-38 payload to be monitored easily invitro and invivo, as inferred from cell studies and exvivo analyses of mice xenografts derived from HeLa cells, respectively. Prodrug 4a also displays anticancer activity in the HeLa cell murine xenograft tumor model. On the basis of these findings we suggest that the present strategy, which combines within a single agent the key functions of targeting, release, imaging, and treatment, may have a role to play in cancer diagnosis and therapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Science > Department of Chemistry > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.